EVERSANA and OptimizeRx Partnership
EVERSANA, an independent provider of global services to the life science industry, and OptimizeRx Corp., a digital health messaging platform focused on affordability and adherence, announced their partnership to integrate a real-time electronic health records (EHR) network and patient services to progress access and adherence for patients.
OptimizeRx’s real-time EHR network will integrate into EVERSANA’s patient support and specialty distribution models to expedite the process from diagnosis and enrollment to affordability solutions and ongoing patient support.
The EHR and patient support service integration will reduce the need for manual, paper-based processing, expedite enrollments, quickly identify affordability and copay programs, and drive proactive adherence support services offered by both the provider and specialty HUB services.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
